Praxis Precision Medicines Reports POWER1 Phase 2/3 Vormatrigine Results

What Happened
Praxis Precision Medicines announced on June 1, 2026 that the Phase 2/3 POWER1 study of vormatrigine in patients with focal onset seizures (FOS) did not meet its primary success measure. The trial did, however, meet a secondary measure—the 50% responder rate—and seizure reduction was more pronounced in the study’s second half at the higher 30 mg dose. Vormatrigine was generally well tolerated; adverse event–related discontinuations were under 10%.

Key Details

• POWER1 primary endpoint not met (filed June 1, 2026).
• Secondary endpoint (50% response rate) met; greater seizure reduction observed in second half on 30 mg dose.
• Adverse event–related discontinuations <10%.
• About 90% of patients from the vormatrigine arm transitioned to and remain in the open-label extension.
• Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program and consider modifications.

Why It Matters
A missed primary endpoint is a material development for Praxis’s clinical program and increases uncertainty around the timing and prospects for regulatory approval. The positive secondary result and stronger effect at the higher dose provide a possible signal that could inform next steps, but the company has paused POWER2 enrollment to reassess. Investors should note this may change development timelines and program strategy; the filing also contains customary forward-looking statement disclaimers.